98%
921
2 minutes
20
Purpose: To investigate the influence of subretinal injection pressure on the microstructure of the retina in a monkey model.
Methods: After vitrectomy, balanced salt solution was injected subretinally into one eye each of four cynomolgus monkeys while controlling the injection pressure. Initially, a pressure of 2 psi was used, and this was gradually increased to determine the minimum required pressure. Subsequent injections were performed at two pressures: minimum (n = 13) and high (n = 6). To compare the influence of these injection pressures on retinal structure, optical coherence tomography (OCT) was performed before surgery and every week afterwards. The monkeys were euthanized and their eyes were enucleated at 1 or 6 weeks after the injections. The eyes were processed for light microscopy and transmission electron microscopy (TEM) as well as for TdT-mediated dUTP nick end labeling.
Results: The minimum pressure required to perform subretinal injection was 6 psi. After injection at this pressure, both OCT and microscopy showed that the retinal structure was well-preserved throughout the experimental period at all injection sites. Conversely, after injection at high pressure (20 psi) OCT images at all injection sites showed disruption of the ellipsoid zone (EZ) after 1 week. Microscopy indicated damage to the photoreceptor outer segment (OS) and stratification of the retinal pigment epithelium (RPE). After 6 weeks, OCT demonstrated that the EZ had become continuous and TEM confirmed that the OS and RPE had recovered. Photoreceptor apoptosis was absent after subretinal injection at both pressures.
Conclusions: The retinal damage caused by subretinal injection increases depending on pressure, indicating that clinicians should perform subretinal injection at pressures as low as possible to ensure safety.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312337 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209996 | PLOS |
Sci Adv
September 2025
Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.
Subretinal injection of adeno-associated virus (AAV) is generally more efficacious and less inflammatory than intravitreal injection for retinal gene therapy. However, adverse events (e.g.
View Article and Find Full Text PDFOphthalmol Sci
July 2025
Japan Community Healthcare Organization, Tokyo, Japan.
Purpose: We report the efficacy and safety of voretigene neparvovec (VN) as an adeno-associated viral vector-based gene therapy for Japanese patients with inherited retinal dystrophy caused by biallelic pathogenic variants (-retinopathy).
Design: Open-label, single arm, phase III clinical trial.
Participants: Four subjects were recruited based on the following criteria: (1) a clinical and molecular genetic diagnosis of -retinopathy; (2) age ≥4 years; (3) a best-corrected VA (BCVA) worse than 20/60 or a visual field (VF) <20° by a III4e isopter or equivalent; and (4) sufficient viable retinal cells by OCT or ophthalmoscopy.
Am J Ophthalmol Case Rep
September 2025
University Eye Clinic Maastricht, MUMC+, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands.
Purpose: To report a case of stellate multiform amelanotic choroidopathy (SMACH) with focal hyperfluorescence on indocyanine green angiography (ICGA), successfully treated with photodynamic therapy (PDT).
Observations: An 18-year-old male presented with subretinal fluid (SRF) overlying an irregular lesion in the inner choroid. A diagnosis of probable idiopathic macular neovascularization was made; treatment with intravitreal injections (IVIs) of anti-vascular endothelial growth factor (VEGF) agents showed no effect.
Eur J Ophthalmol
September 2025
Department of Ophthalmology, APHM, Hôpital Nord, Marseille, France.
ObjectiveTo evaluate the efficacy of switching from anti-vascular endothelial growth factor (VEGF) to faricimab in reducing exudative signs in age-related macular degeneration (AMD) patients receiving regular injections (every 8 weeks or less) without restarting a standard induction regimen.MethodsThis retrospective, observational, multicenter study included patients with exudative AMD previously treated with aflibercept 2 mg or ranibizumab every ≤8 weeks and switched to faricimab while maintaining their previous injection interval. The first follow-up visit occured after switching to faricimab, with a single injection, and corresponded to the pre-existing injection interval.
View Article and Find Full Text PDFSci Rep
August 2025
Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Ocular Inflammation Group, Barcelona, Spain.
Choroidal neovascularization (CNV) and inflammation play an important role in retinal disease development and the acute phase reactant C-reactive protein (CRP) has been shown to contribute to Age-related macular degeneration (AMD) in vitro. Our aim was to evaluate whether monomeric and pentameric CRP (pCRP, mCRP) isoforms contribute to CNV in vivo and to characterize the mechanism of CRP dissociation in-vivo and in vitro. Both CRP isoforms were intravitreally (IVT) or intravenously (IV) injected in mice, CNV was laser-induced, retinography and fluorescein angiography were performed to evaluate edema.
View Article and Find Full Text PDF